KCNH2 and cancer: Overall, the evidence provided in the present paper pleads for the cardiac safety of the scDb-hERG1-β1, suggesting even if with preliminary data, that an application of this antibody to anti-cancer therapy will be untainted by cardiotoxicity, preventing a pathological prolongation of repolarization that could lead to the long QT type 2 (LQT2) syndrome and the related fatal arrhythmia.